Table 2.

Overall survival results of 2 randomised controlled studies comparing atezolizumab vs. systemic chemotherapy with proton pump inhibitor (PPI) users versus non-users. HR: hazard ratio of overall survival of atezolizumab versus chemotherapy.

Trial	Subgroup	n	HR (95%CI)
POPLAR	PPI users	494	0.92 (0.75–1.44)
n = 1512 [58]	PPI non-users	1018	0.73 (0.62–0.85)
IMvigor 211	PPI users	330	1.04 (0.81–1.34)
N = 931 [59]	PPI non-users	601	0.69 (0.56–0.84)